参考文献/References:
[1]Paola Portillo-Sanchez,Kenneth Cusi.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes[J].Clinical Diabetes and Endocrinology,2016(2):9.
[2]Targher G,Byrne CD.Non-alcoholic fatty liver disease:an emerging driving force in chronic kidney disease[J].Nat Rev Nephrol,2017,2(20):263-269.
[3]Yabiku K,Mutoh A,Miyagi K,et al.Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computerd tomograghy and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease[J].Clin Ther,2017,2(6):5715-5719.
[4]William T,Cefalu MD.Standards of medical care in diadetes-2017[J].Diabetes Care January,2017(40):1.
[5]Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology,2012,55(6):2005-2023.
[6]Singal AG,Manjunath H,Yopp AC,et al.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis[J].Am J Gastroenterol,2014,109(3):325-334.
[7]Bril F,Cusi K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action[J].Diabetes Care,2017,40(3):419-430.
[8]Inzucchi SE,Bergenstal RM,Buse JB.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach.Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetologia,2015(58):429-442.
[9]Siddiqui MS,Fuchs M,Idowu MO,et al.Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile[J].Clin Gastroenterol Hepatol,2015(13):1000-1008.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(23):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(23):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(23):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(23):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Journal of Medical Information,2018,31(23):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[6]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(23):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[7]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(23):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[8]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(23):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[9]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[10]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(23):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]